Skip to main navigation
Skip to search
Skip to main content
MD Anderson Cancer Center Home
Help & FAQ
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Search by expertise, name or affiliation
Dasatinib, an immunomodulator?
Farhad Ravandi
Leukemia
Research output
:
Contribution to journal
›
Comment/debate
›
peer-review
5
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Dasatinib, an immunomodulator?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Dasatinib
92%
Imatinib Mesylate
76%
Immunologic Factors
72%
Lymphocytosis
43%
Natural Killer Cells
31%
Protein-Tyrosine Kinases
30%
T-Lymphocytes
20%
Therapeutics
10%
Chemistry
Imatinib
100%
Tyrosine Kinase Inhibitor
46%